In two articles in this issue of the Journal, the members of the GRADE Study Research Group1,2 report the findings of the Glycemia Reduction Approaches in Type 2 Diabetes: A Comparative Effectiveness (GRADE) Study, which involved participants who had type 2 diabetes without established cardiovascular complications. These articles have been awaited with great anticipation. Most advances related to cardiovascular benefit in the treatment of type 2 diabetes have been derived from cardiovascular outcome trials involving participants with previous cardiovascular disease, and these advances have been related to secondary prevention. On the basis of those trials, the availability of two new . . .